Therapy News and Research

RSS

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.

4 Nov 2008

Genetic mutation linked to seasonal affective disorder

With the days shortening toward winter, many people will begin to experience the winter blahs.

4 Nov 2008

Adding protein sarcospan to muscle cells might help Duchenne muscular dystrophy

The overlooked and undervalued protein, sarcospan, just got its moment in the spotlight.

4 Nov 2008

Call to explore broader use of human papillomavirus vaccines

A call to explore a broader use of HPV (human papillomavirus) vaccines and the validation of a simple oral screening test for HPV-caused oral cancers are reported in two studies by a Johns Hopkins Kimmel Cancer Center investigator.

4 Nov 2008

Phase 2 trial of treatment of C-difficile-associated diarrhea shows promise

Medarex, Inc. and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti- C. difficile antibody combination treatment in patients with C.

4 Nov 2008

Novel leukemia therapy shows promise for high-risk patients

Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.

4 Nov 2008

Two different approaches used to correct clubfoot both bring positive outcomes for most children

Two non-surgical treatments most commonly used to correct the condition known as clubfoot have similarly high levels of success, according to a new study published in the November 2008 issue of The Journal of Bone and Joint Surgery.

4 Nov 2008

Human papillomavirus helps cervical and head and neck cancers resist treatment and grow and spread

The human papillomavirus (HPV) allows infected cervical and head and neck cancer cells to maintain internal molecular conditions that make the cancers resistant to therapy and more likely to grow and spread, resulting in a poor prognosis for patients, researchers with UCLA's Jonsson Cancer Center found.

4 Nov 2008

Long-term benefits of morphine treatment in infants confirmed

A recent study conducted by researchers at Georgia State University is the first of its kind to demonstrate that administration of preemptive morphine prior to a painful procedure in infancy blocks the long-term negative consequences of pain in adult rodents.

4 Nov 2008

Cone-beam CT compared to MDCT before and after percutaneous vertebroplasty

Cone-beam CT which is believed to deliver less radiation than MDCT is just as useful when evaluating patients before and after percutaneous vertebroplasty according to a study performed at the Department of Clinical Radiology, Kyushu University, Fukoka, Japan.

4 Nov 2008

Novel approach to help drivers with ADHD

If your teen can't pass a driver's test, it might not mean more time in driver's ed is needed. It might be due to ADHD!

4 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

Anti-VEGF drugs for retinal diseases could have serious side effects

Scientists at Schepens Eye Research Institute have found that reducing the levels of vascular endothelial growth factor (VEGF), which is best known as a stimulator of new blood vessel growth, in adult mice causes the death of photoreceptors and Muller glia -- cells of the retina that are essential to visual function.

3 Nov 2008

Scientist says research indicates need for effective HPV vaccine for women and men and a simple HPV screening test

3 Nov 2008

Genentech submits application to FDA for Avastin in the most aggressive form of brain cancer

Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.

3 Nov 2008

Researchers develop DNA vaccine for West Nile virus

Researchers are developing a DNA-based vaccine against the dreaded West Nile virus (WNV), which can be transmitted from animals to humans. The unique feature of this vaccine is that it is also effective after onset of the disease, for it has therapeutic properties.

3 Nov 2008

Magnet restores colour perception in partially-sighted patient

A researcher from the University of Essex has succeeded in inducing the experience of colour in the blind part of a partially sighted patient's visual field.

3 Nov 2008

Two pronged approach to melanomas shows promise

An international team of researchers have developed a new substance which uses a two pronged attack on malignant cells.

3 Nov 2008

Double-barreled immune cell approach for neuroblastoma

Adding an artificial tumor-specific receptor to immune system cells called T-lymphocytes that target a particular virus extended and improved the cells' ability to fight a form of childhood cancer called neuroblastoma, said researchers form Baylor College of Medicine and Texas Children's Hospital in a report that appears online in the journal Nature Medicine.

2 Nov 2008

Substance tackles skin cancer with two-pronged attack

By playing it safe and using a two-pronged attack, a novel designer molecule fights malignant melanoma. It was created and tested by an international team of researchers led by the University of Bonn.

2 Nov 2008